These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 2783891)

  • 1. Effect of anticancer agents neothramycin, aclacinomycin, FK-565 and FK-156 on the release of interleukin-2 and interleukin-1 in vitro.
    Ahmed K; Turk JL
    Cancer Immunol Immunother; 1989; 28(2):87-92. PubMed ID: 2783891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of anticancer drugs on the release of interferon gamma in vitro.
    Ahmed K; van der Meide PH; Turk JL
    Cancer Immunol Immunother; 1989; 30(4):213-8. PubMed ID: 2480848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunoactive peptides, FK 156 and FK 565. IV. Activation of mouse macrophages.
    Watanabe Y; Tawara S; Mine Y; Kikuchi H
    J Antibiot (Tokyo); 1985 Dec; 38(12):1781-7. PubMed ID: 3005214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of adriamycin, 4-hydroperoxycyclophosphamide and ASTA Z 7557 (INN mafosfamide) on the release of IL-2 and IL-1 in vitro.
    Abdul Hamied TA; Parker D; Turk JL
    Int J Immunopharmacol; 1987; 9(3):355-61. PubMed ID: 3497116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Immunomodulation by antitumor antibiotics].
    Ishizuka M
    Gan To Kagaku Ryoho; 1986 Mar; 13(3 Pt 2):697-700. PubMed ID: 3963840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potentiation of release of interleukin-2 by bleomycin.
    Abdul Hamied TA; Parker D; Turk JL
    Immunopharmacology; 1986 Oct; 12(2):127-34. PubMed ID: 2429940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aclacinomycin, an anti-leukemic anthracycline, impairs human neutrophil functions.
    Katoh M; Fukuhara Y; Chiba T; Shirai T; Kitagawa S; Kakinuma K
    Int J Hematol; 1991 Feb; 54(1):49-55. PubMed ID: 1659466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced production of interleukin 1 by mouse peritoneal macrophages after aclacinomycin administration.
    Bravo-Cuellar A; Martin-Ruiz JL; Liu XH; Orbach-Arbouys S
    Immunol Lett; 1990 Jan; 23(3):165-72. PubMed ID: 2307488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Macrophage involvement in the antitumor activity of a synthetic acyltripeptide (FK-565) against experimental lung carcinoma metastases.
    Schultz RM; Altom MG
    J Immunopharmacol; 1986; 8(4):515-28. PubMed ID: 3543138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancement of immune responses and possible inhibition of suppressor cells by aclacinomycin A.
    Ishizuka M; Takeuchi T; Masuda T; Fukasawa S; Umezawa H
    J Antibiot (Tokyo); 1981 Mar; 34(3):331-40. PubMed ID: 6456249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mitogenic potentials of bestatin, amastatin, arphamenines A and B, FK-156 and FK-565 on spleen lymphocytes.
    Weissmann N; Leyhausen G; Maidhof A; Tanaka W; Umezawa H; Müller WE
    J Antibiot (Tokyo); 1985 Jun; 38(6):772-8. PubMed ID: 4019321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunoactive peptides, FK-156 and FK-565. II. Restoration of host resistance to microbial infection in immunosuppressed mice.
    Yokota Y; Mine Y; Wakai Y; Watanabe Y; Nishida M; Goto S; Kuwahara S
    J Antibiot (Tokyo); 1983 Aug; 36(8):1051-8. PubMed ID: 6415030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of release of interleukin-2 by vincristine and vinblastine.
    Ahmed K; Abdul Hamied TA; Turk JL
    Immunopharmacol Immunotoxicol; 1987; 9(4):391-407. PubMed ID: 3501797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Studies on structure-activity relationships of FK-156, an immunostimulating peptide, and related compounds. I. Synthesis of stereoisomeric analogues of FK-156.
    Takeno H; Okada S; Hemmi K; Aratani M; Kitaura Y; Hashimoto M
    Chem Pharm Bull (Tokyo); 1984 Aug; 32(8):2925-31. PubMed ID: 6518578
    [No Abstract]   [Full Text] [Related]  

  • 15. [Low molecular weight immunomodulators produced by microorganisms].
    Ishizuka M
    Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 2):2709-14. PubMed ID: 6508323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased release of interleukin-1 and tumour necrosis factor by interleukin-2-induced lymphokine-activated killer cells in the presence of cisplatin and FK-565.
    Basu S; Sodhi A
    Immunol Cell Biol; 1992 Feb; 70 ( Pt 1)():15-24. PubMed ID: 1639431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunomodulatory and therapeutic properties of FK-565 in mice.
    Talmadge JE; Lenz B; Schneider M; Phillips H; Long C
    Cancer Immunol Immunother; 1989; 28(2):93-100. PubMed ID: 2521814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of anticancer drugs on the release of tumour necrosis factor in vitro.
    Hasan SI; Ahmed K; Turk JL
    Cancer Immunol Immunother; 1990; 30(6):363-6. PubMed ID: 2302726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunoactive peptides, FK-156 and FK-565. III. Enhancement of host defense mechanisms against infection.
    Mine Y; Watanabe Y; Tawara S; Yokota Y; Nishida M; Goto S; Kuwahara S
    J Antibiot (Tokyo); 1983 Aug; 36(8):1059-66. PubMed ID: 6630057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancement of interleukin 1 and interleukin 2 releases by ubenimex.
    Shibuya K; Hayashi E; Abe F; Takahashi K; Horinishi H; Ishizuka M; Takeuchi T; Umezawa H
    J Antibiot (Tokyo); 1987 Mar; 40(3):363-9. PubMed ID: 3494719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.